April 12, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key updates are summarized below:

The U.S. Food and Drug Administration (FDA) recently approved long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and adolescents aged ≥12 years and weighing ≥35 kg. This change has been incorporated in the Cabotegravir and Rilpivirine drug sections; other sections have not been updated yet. The Panel has not made revisions to address the recent FDA approval of the dispersible table formulation of the fixed-dose combination (FDC) of abacavir/ dolutegravir/ lamivudine (Triumeq PD) for use in children weighing 10 kg to 25 kg; this will be addressed in a future update.

Other sections of the guidelines were updated:
Clinical and Laboratory Monitoring of Pediatric HIV Infection
What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children
What Not to Start: Regimens Not Recommended for Use in Antiretroviral-Naive Children
Special Considerations for Antiretroviral Therapy Use in Adolescents with HIV
Adherence to Antiretroviral Therapy in Children and Adolescents with HIV
Management of Medication Toxicity or Intolerance
Management of Children Receiving Antiretroviral Therapy
Appendix A: Pediatric Antiretroviral Drug Information

For a complete list of recent updates, please see What’s New in the Guidelines. To view or download the guidelines, go to the Pediatric ARV Guidelines section of Clinical Info’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.